Somatic Mutations Drive Specific, but Reversible, Epigenetic Heterogeneity States in AML.

Epigenesis, Genetic / genetics Female Humans Leukemia, Myeloid, Acute / genetics Male Mutation

Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
12 2020
Historique:
received: 01 08 2019
revised: 09 07 2020
accepted: 11 09 2020
pubmed: 18 9 2020
medline: 25 11 2021
entrez: 17 9 2020
Statut: ppublish

Résumé

Epigenetic allele diversity is linked to inferior prognosis in acute myeloid leukemia (AML). However, the source of epiallele heterogeneity in AML is unknown. Herein we analyzed epiallele diversity in a genetically and clinically annotated AML cohort. Notably, AML driver mutations linked to transcription factors and favorable outcome are associated with epigenetic destabilization in a defined set of susceptible loci. In contrast, AML subtypes linked to inferior prognosis manifest greater abundance and highly stochastic epiallele patterning. We report an epiallele outcome classifier supporting the link between epigenetic diversity and treatment failure. Mouse models with

Identifiants

DOI: 10.1158/2159-8290.CD-19-0897 PMID: 32938585 PMC: PMC7710625
pubmed: 32938585
pii: 2159-8290.CD-19-0897
doi: 10.1158/2159-8290.CD-19-0897
pmc: PMC7710625
mid: NIHMS1630381
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1934-1949

Subventions

Organisme : NCI NIH HHS
ID : R01 CA198089
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA034196
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM133562
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA181507
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233332
Pays : United States

Informations de copyright

©2020 American Association for Cancer Research.

Références

JCI Insight. 2016 Jun 16;1(9):
pubmed: 27446991
PLoS Genet. 2013;9(1):e1003137
pubmed: 23326238
Nucleic Acids Res. 2014 Jan;42(Database issue):D172-7
pubmed: 24185696
Blood. 2016 Sep 29;128(13):1671-8
pubmed: 27421961
J Hematol Oncol. 2019 Jul 8;12(1):72
pubmed: 31286998
BMC Res Notes. 2015 Dec 30;8:832
pubmed: 26714840
Blood. 2009 Oct 15;114(16):3448-58
pubmed: 19652201
Cell Stem Cell. 2008 May 8;2(5):484-96
pubmed: 18462698
Cancer Cell. 2010 Dec 14;18(6):553-67
pubmed: 21130701
Leukemia. 2015 Jul;29(7):1470-7
pubmed: 25976987
PLoS Biol. 2004 Apr;2(4):E108
pubmed: 15094809
Oncogene. 2002 May 13;21(21):3414-21
pubmed: 12032779
Genome Biol. 2014 Sep 27;15(9):472
pubmed: 25260792
Oncogene. 2001 Apr 30;20(19):2378-89
pubmed: 11402334
Cancer Cell. 2014 Dec 8;26(6):813-825
pubmed: 25490447
Cancer Cell. 2010 Jan 19;17(1):13-27
pubmed: 20060365
PLoS Genet. 2012;8(6):e1002781
pubmed: 22737091
J Clin Invest. 2013 Jan;123(1):299-314
pubmed: 23202735
J Biol Chem. 2016 May 20;291(21):11148-60
pubmed: 27044748
Leukemia. 2017 May;31(5):1196-1205
pubmed: 27840425
Blood. 2009 Mar 19;113(12):2795-804
pubmed: 19168792
Blood. 2002 Jan 1;99(1):252-7
pubmed: 11756179
Nat Med. 2016 Jul;22(7):792-9
pubmed: 27322744
Cell Rep. 2014 Dec 11;9(5):1841-1855
pubmed: 25482556
Nucleic Acids Res. 2016 Jan 4;44(D1):D917-24
pubmed: 26507857
Gene. 2000 Dec 30;260(1-2):1-12
pubmed: 11137286
Blood. 2000 Jan 1;95(1):19-29
pubmed: 10607680
Cancer Cell. 2015 Apr 13;27(4):502-15
pubmed: 25873173
Nat Genet. 2012 Nov;44(11):1207-14
pubmed: 23064413
Blood. 2009 Mar 26;113(13):3088-91
pubmed: 19171880
N Engl J Med. 2013 May 30;368(22):2059-74
pubmed: 23634996
Nat Commun. 2015 Apr 20;6:6921
pubmed: 25891015
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7452-6
pubmed: 1502157
Cancer Cell. 2011 Jul 12;20(1):11-24
pubmed: 21723200
Cancer Discov. 2017 Aug;7(8):868-883
pubmed: 28408400
Nat Commun. 2018 Jan 15;9(1):222
pubmed: 29335468
J Clin Invest. 2015 May;125(5):1857-72
pubmed: 25822018
Cancer Discov. 2017 May;7(5):494-505
pubmed: 28193779
JAKSTAT. 2013 Oct 1;2(4):e27159
pubmed: 24498540
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Leukemia. 2014 Apr;28(4):770-8
pubmed: 24002588
Cancer Cell. 2010 Feb 17;17(2):173-85
pubmed: 20159609
Oncotarget. 2015 Mar 20;6(8):5490-500
pubmed: 25823927
EMBO Mol Med. 2010 Mar;2(3):98-110
pubmed: 20201032
Oncogene. 2003 Jul 24;22(30):4760-4
pubmed: 12879022
Nature. 2012 Jan 11;481(7382):506-10
pubmed: 22237025
Cell. 2017 Feb 23;168(5):801-816.e13
pubmed: 28215704

Auteurs

Sheng Li (S)

The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut. amm2014@med.cornell.edu sheng.li@jax.org.
The Jackson Laboratory Cancer Center, Bar Harbor, Maine.
The Department of Genetics and Genomic Sciences, The University of Connecticut Health Center, Farmington, Connecticut.
Department of Computer Science and Engineering, University of Connecticut, Storrs, Connecticut.
ORCID: 0000-0002-9543-6274

Xiaowen Chen (X)

The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.

Jiahui Wang (J)

The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.

Cem Meydan (C)

Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York.
ORCID: 0000-0002-0663-6216

Jacob L Glass (JL)

Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Alan H Shih (AH)

Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.

Ruud Delwel (R)

Department of Hematology, Erasmus University Medical Center and Oncode Institute, Rotterdam, the Netherlands.

Ross L Levine (RL)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Christopher E Mason (CE)

Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York.
ORCID: 0000-0002-1850-1642

Ari M Melnick (AM)

Division of Hematology/Oncology, Weill Cornell Medicine, New York, New York. amm2014@med.cornell.edu sheng.li@jax.org.
ORCID: 0000-0002-8074-2287

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Épigenèse génétique › Somatic Mutations Drive Specific, but...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Somatic Mutations Drive Specific, but...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › Somatic Mutations Drive Specific, but...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Somatic Mutations Drive Specific, but...